This meta-analysis found that zanamivir, an antiviral neuraminidase inhibitor, reduced the time to symptomatic improvement in adults (but not children) with influenza. Adults treated with zanamivir had symptom relief about 12 hours earlier than adults not treated with zanamivir. The authors found NO evidence that zanamivir reduced the risk of influenza complications such as pneumonia, hospital admissions, or death. Side effects were minor except for bronchospasm. Use for prophylaxis was not found to be of significant benefit.
BMJ. 2014 Apr 9;348:g2547 (retrieved May, 2014).
There are currently 1090 pearls in the database. While every attempt has been made to ensure accuracy, mistakes can and do occur. Use databank at your own risk.
All pearls © 2024 by the Internet Medical Association. Click Here to view more medical pearls.
|